NASDAQ:LIMN Liminatus Pharma 10/4/2025 Earnings Report $0.19 +0.00 (+1.08%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Liminatus Pharma EPS ResultsActual EPS-$0.05Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ALiminatus Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ALiminatus Pharma Announcement DetailsQuarterDate10/4/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Liminatus Pharma Earnings HeadlinesLiminatus Pharma, Inc. Class AMarch 31, 2026 | edition.cnn.comLiminatus Pharma Announces Planned Phase 1 Clinical Trial of IBA101, a Next-Generation CD47 Blocking AntibodyMarch 17, 2026 | globenewswire.comDistracted Americans set to miss out on quadrillionsTechnology expert and Washington D.C. insider Jeff Brown - who identified Bitcoin, Tesla, and Nvidia early - says hundreds of trillions of dollars are about to move through a new financial technology that has nothing to do with AI. Goldman Sachs, Citi, Chase, and 50-plus major institutions are already preparing. A key piece of legislation expected before July could fast-track global adoption. Jeff is sharing his full research at no charge.May 14 at 1:00 AM | Brownstone Research (Ad)Liminatus Pharma Lowers Quorum Requirement in Bylaw AmendmentMarch 10, 2026 | theglobeandmail.comLiminatus Pharma, Inc. Announces Pricing of $4.0 Million Public OfferingFebruary 17, 2026 | globenewswire.comLiminatus Pharma, Inc. Class A Common Stock (LIMN) ChartsJanuary 21, 2026 | nasdaq.comSee More Liminatus Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Liminatus Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Liminatus Pharma and other key companies, straight to your email. Email Address About Liminatus PharmaLiminatus Pharma (NASDAQ:LIMN), Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.View Liminatus Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Nebius Upside Expands as AI Feedback Loop IntensifiesOklo Stock Could Be Ready for Another Massive RunAmazon vs. Alibaba: One Is Clearly The Better Value Play right NowD-Wave Earnings Looked Weak, But Investors May Be Missing ThisThe Great SPR Arbitrage: An Oil Market Glitch Fuels Sector GainsA New Focus for GoPro: Is a Takeover in the Frame?Chime Finally Turns Profitable—But Risks Remain Upcoming Earnings Mizuho Financial Group (5/15/2026)Palo Alto Networks (5/19/2026)Home Depot (5/19/2026)Keysight Technologies (5/19/2026)Analog Devices (5/20/2026)Intuit (5/20/2026)NVIDIA (5/20/2026)Lowe's Companies (5/20/2026)Medtronic (5/20/2026)Target (5/20/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
